Get the Stockscreener App
33.65
2.65%
0.87
After Hours:
33.65
Kiniksa Pharmaceuticals International Plc stock is traded at $33.65, with a volume of 572.92K.
It is up +2.65% in the last 24 hours and up +19.79% over the past month.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
See More
Previous Close:
$32.78
Open:
$32.96
24h Volume:
572.92K
Relative Volume:
0.75
Market Cap:
$1.46B
Revenue:
$384.10M
Net Income/Loss:
$-9.07M
P/E Ratio:
-240.36
EPS:
-0.14
Net Cash Flow:
$11.10M
1W Performance:
+2.84%
1M Performance:
+19.79%
6M Performance:
+71.25%
1Y Performance:
+30.83%
1-Day Range:
$32.69
$33.66
1-Week Range:
$31.78
$33.68
52-Week Range:
$17.82
$33.98
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Company Profile
Name
Kiniksa Pharmaceuticals International Plc
Sector
Phone
(781) 431-9100
Address
23 OLD BOND STREET, FLOOR 3, LONDON
Compare KNSA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KNSA
Kiniksa Pharmaceuticals International Plc
|
33.65 | 2.43B | 384.10M | -9.07M | 11.10M | -0.14 |
|
ZTS
Zoetis Inc
|
152.44 | 66.04B | 9.39B | 2.61B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.77 | 45.57B | 29.98B | 958.27M | 5.31B | 0.2964 |
|
HLN
Haleon Plc Adr
|
9.69 | 42.50B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.21 | 18.84B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
309.72 | 13.59B | 2.99B | 1.21B | 1.13B | 25.06 |
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-25 | Initiated | Citigroup | Buy |
| Sep-13-24 | Initiated | Jefferies | Buy |
| May-03-24 | Initiated | Wells Fargo | Overweight |
| Jun-29-20 | Reiterated | BofA Securities | Buy |
| Apr-01-20 | Initiated | BofA/Merrill | Buy |
| Mar-11-19 | Initiated | Barclays | Overweight |
| Dec-12-18 | Reiterated | Wedbush | Outperform |
| Jun-19-18 | Initiated | JMP Securities | Mkt Outperform |
View All
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Latest News
Insider Selling: Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Insider Sells 29,325 Shares of Stock - MarketBeat
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Shares Purchased by Connor Clark & Lunn Investment Management Ltd. - MarketBeat
Eben Tessari Sells 138,614 Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Stock - MarketBeat
Michael R. Megna Sells 17,000 Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Stock - MarketBeat
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) CFO Sells $621,259.21 in Stock - MarketBeat
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Sets New 12-Month HighShould You Buy? - MarketBeat
BIT Capital GmbH Takes $264,000 Position in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) - MarketBeat
Kiniksa Pharmaceuticals International, plc (KNSA) Is Up 21.46% in One Week: What You Should Know - Yahoo Finance
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Upgraded at Wall Street Zen - Defense World
Wedbush Issues Positive Outlook for KNSA Earnings - MarketBeat
Kiniksa Pharmaceuticals surges 11.01% on Arcalyst's market penetration - AInvest
Victory Capital Management Inc. Makes New Investment in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) - MarketBeat
Does Kiniksa Pharmaceuticals International, plc (KNSA) Have the Potential to Rally 35.96% as Wall Street Analysts Expect? - MSN
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Sets New 12-Month High After Earnings Beat - MarketBeat
Equities Analysts Set Expectations for KNSA Q3 Earnings - Defense World
Why Kiniksa Pharmaceuticals International, plc (KNSA) Might be Well Poised for a Surge - Yahoo Finance
Here's Why Momentum in Kiniksa Pharmaceuticals International, plc (KNSA) Should Keep going - Yahoo Finance
Victory Capital Management Inc. Takes $1.18 Million Position in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) - Defense World
Kiniksa Pharmaceuticals Achieves 52% YoY Growth in Q2 2025, Raises Revenue Guidance - AInvest
Kiniksa Pharmaceuticals International, plc (KNSA) Tops Q2 Earnings and Revenue Estimates - MSN
Kiniksa raises ARCALYST 2025 revenue guidance to $625M-$640M as patient penetration rises - MSN
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q2 2025 Earnings Call Transcript - Insider Monkey
Kiniksa Pharmaceuticals International Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Kiniksa Pharmaceuticals International PLC (KNSA) Q2 2025 Earnings Call Highlights: Record ... - Yahoo Finance
Kiniksa Pharmaceuticals International PLC (KNSA) Q2 2025 Earnings Call Highlights: Record ... By GuruFocus - Investing.com Canada
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Hits New 1-Year High After Strong Earnings - Defense World
Kiniksa Pharmaceuticals Reports Strong Q2 2025 Growth - TipRanks
Kiniksa: Jefferies maintains Buy, raises PT to $54 from $45. - AInvest
Kiniksa Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution - GlobeNewswire
Kiniksa Pharmaceuticals Q2 2025 Earnings Call Transcript: Key Highlights and Financial Results - AInvest
Kiniksa Pharmaceuticals stock hits 52-week high at 30.8 USD By Investing.com - Investing.com Nigeria
Kiniksa Pharmaceuticals International Q2 2025 Earnings Call Transcript - MarketBeat
Kiniksa Pharmaceuticals Reports Q2 2025 Financial Results with 52% Growth in ARCALYST Revenue and Updates on Clinical Trials - Quiver Quantitative
Kiniksa Crushes Earnings: ARCALYST Sales Jump 52%, Company Raises 2025 Revenue Target to $640M - Stock Titan
Kiniksa Pharmaceuticals Q2 2025 Earnings Preview: $0.22 EPS, $145.21M Revenue Expected - AInvest
Cwm LLC Purchases 19,828 Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) - MarketBeat
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Given Average Rating of “Buy” by Analysts - Defense World
Analysts Set Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) PT at $39.67 - MarketBeat
Kiniksa Pharmaceuticals Announces Q2 2025 Financial Results Conference Call. - AInvest
Kiniksa Pharmaceuticals International PLC expected to post earnings of 18 cents a shareEarnings Preview - TradingView
Cwm LLC Has $491,000 Holdings in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) - Defense World
Kiniksa Pharmaceuticals to Report Second Quarter 2025 Financial Results on July 29, 2025 - GlobeNewswire
Kiniksa Pharmaceuticals Q2 2025 Earnings: Key Financial Results Coming July 29How to Join - Stock Titan
Cerity Partners LLC Boosts Stock Holdings in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) - Defense World
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):